deCODE genetics (DCGN) Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
More News related to DCGN
- deCODE genetics (DCGN) Receives Trading Suspension Letter From Nasdaq
- deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal
- deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
- deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets
- After-Hours Movers 9/17: IHS, GEOY Higher; CLUB, FSP, NMM, SIRI Lower
Scientists at deCODE genetics (Nasdaq: DCGN) and colleagues from Europe and the United States today report the discovery of a common single-letter variant in the sequence of the human genome conferring increased risk of atrial fibrillation (AF) and stroke. The findings will be integrated directly into the deCODE AF(TM) reference laboratory test for gauging individual risk of AF and stroke and helping to identify stroke patients who may benefit from enhanced monitoring for AF. The study is published online today in Nature Genetics at http://www.nature.com/ng.
More from the release.
Related Categories
Corporate NewsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
